The Growth Factor Signature (GFS) as an Intermediate Biomarker of Response for Development of PI3K-Pathway Inhibitors in Patients With Breast Cancer (MK-8669-050)
Clinical trial NCT01220570 · COMPLETED
Trial details
- NCT number
- NCT01220570
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2010-09-01
- Primary completion
- 2012-12-01
- Enrollment
- 63
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.